{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000089","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.384975+00:00","generated_at":"2026-06-14T06:05:03.072542+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Xeris Biopharma stockholders elect three Class II directors and ratify E&Y as auditor at 2023 annual meeting","bullets":["Dawn Halkuff elected with 53.2M for, 4.4M withhold, 31.2M broker non-votes.","John Johnson elected with 42.9M for, 14.7M withhold, 31.2M broker non-votes.","Jeffrey Sherman elected with 51.3M for, 6.3M withhold, 31.2M broker non-votes.","Ratification of Ernst & Young as auditor approved: 87.8M for, 0.8M against, 0.2M abstain.","No other matters were submitted to a vote at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000089","json":"https://secwatch.observer/filing/0001867096-23-000089.json","markdown":"https://secwatch.observer/filing/0001867096-23-000089.md","text":"https://secwatch.observer/filing/0001867096-23-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/xers-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:05:03.072542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9f5a90ba316ee4c1e90597ff05e440a067e0102","claim":"Xeris Biopharma Holdings, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.","evidence_excerpt":"The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows*: For Against Abstain 87,826,099 820,583 239,701","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"bf53f21b3657eb92679e9dff2402b84e49395150","claim":"Xeris Biopharma Holdings, Inc. shareholders approved To elect Dawn Halkuff, John Johnson and Jeffrey Sherman as Class II directors at the 2023-06-07 meeting.","evidence_excerpt":"The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 7, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm","confidence":0.99,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}